8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Complete guide to Praluent (alirocumab) compounding legal status, FDA approval history, patent protections, and regulatory framework governing PCSK9 inhibitor access.
A clinical review of alirocumab (Praluent) safety signals from the FDA Adverse Event Reporting System (FAERS), post-market surveillance findings, and label updates since approval.
Complete FDA approval timeline for Praluent (alirocumab), including original 2015 approval, ODYSSEY OUTCOMES cardiovascular indication, labeling changes, and post-market safety data.
Complete regulatory overview of Praluent (alirocumab), including FDA approval history, EMA authorization, ODYSSEY OUTCOMES cardiovascular indication, label expansions, and post-market safety surveillance.
Complete regulatory timeline for Praluent (alirocumab), including FDA approval history, current label indications, post-market safety data, and next-generation PCSK9 inhibitor development.
A side-by-side comparison of how the FDA and EMA regulate Praluent (alirocumab), covering approval timelines, label differences, indication scope, post-market surveillance, and safety monitoring.
A detailed look at Praluent's FDA approval, the landmark Amgen v. Sanofi patent dispute, label expansions, safety data from ODYSSEY OUTCOMES, and what these legal and regulatory events mean for PCSK9 inhibitor access.
A complete regulatory history of Praluent (alirocumab) label changes from 2020 to 2026, including dosing updates, cardiovascular outcome data from ODYSSEY OUTCOMES, safety revisions, and current FDA prescribing guidance.